MedTrace Logo

Biomarkers for Hunter Syndrome

NCT01330277 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 11

Last updated 2023-02-10

No results posted yet for this study

Summary

International, multicenter, observational, longitudinal study to establish Hunter Syndrom biomarker/s and to explore the clinical robustness, specificity, and long-term variability of these biomarker/s

Conditions

  • Hunter Syndrome
  • Mucopolysaccharidosis II
  • Hunter's Syndrome, Mild Form
  • Hunter's Canal Syndrome

Sponsors & Collaborators

  • CENTOGENE GmbH Rostock

    lead INDUSTRY

Principal Investigators

  • Arndt Rolfs, Prof. Dr. · CENTOGENE GmbH Rostock

Eligibility

Min Age
2 Months
Max Age
50 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-20
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01330277 on ClinicalTrials.gov